Notable
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Primary completion pushed from Aug 2026 to Jul 2027
Also in this update: Study completion pushed from Oct 2026 to Oct 2027
Curis, Inc.Phase 1/2 NCT03328078 Registry history of NCT03328078 on ClinicalTrials.gov (opens the registry)